Open AccessCerebrospinal Fluid Dehydroepiandrosterone Levels Are Correlated with Brain Dehydroepiandrosterone Levels, Elevated in Alzheimer’s Disease, and Related to Neuropathological Disease Stage
Author(s) -
Jennifer C. Naylor,
Christine M. Hulette,
David C. Steffens,
Lawrence J. Shampine,
John F. Ervin,
Victoria M. Payne,
Mark W. Massing,
Jason D. Kilts,
Jennifer Strauss,
Patrick S. Calhoun,
Rohana P. Calnaido,
Daniel Blazer,
Jeffrey A. Lieberman,
Roger D. Madison,
Christine E. Marx
Publication year - 2008
Publication title -
the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2007-1229
Subject(s) - dehydroepiandrosterone , neuroactive steroid , pregnenolone , medicine , endocrinology , cerebrospinal fluid , alzheimer's disease , dehydroepiandrosterone sulfate , psychology , androgen , disease , steroid , receptor , hormone , gabaa receptor
It is currently unknown whether cerebrospinal fluid (CSF) neurosteroid levels are related to brain neurosteroid levels in humans. CSF and brain dehydroepiandrosterone (DHEA) levels are elevated in patients with Alzheimer's disease (AD), but it is unclear whether CSF DHEA levels are correlated with brain DHEA levels within the same subject cohort. We therefore determined DHEA and pregnenolone levels in AD patients (n = 25) and cognitively intact control subjects (n = 16) in both CSF and temporal cortex.